Darigabat for Panic Disorder

Recruiting at 30 trial locations

Overseen By Theresa Pham

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: AbbVie

Disqualifiers: Psychiatric comorbidity, Cardiovascular, Neurological, others

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This trial is testing if taking darigabat regularly can help people with panic disorder by calming their brain activity to reduce panic attacks.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.

What data supports the effectiveness of the drug Darigabat for panic disorder?

There is evidence that treatments affecting the GABA system, like tiagabine, can help with panic disorder, suggesting that Darigabat, which also targets GABA, might be effective. ^{1 2 3 4 5}

How does the drug Darigabat differ from other treatments for panic disorder?

Darigabat is unique because it targets the GABA system, which is believed to play a role in panic disorder, offering a new approach compared to traditional treatments like moclobemide and clomipramine that focus on different mechanisms. ^{1 5 6 7 8}

Research Team

ABBVIE INC.

Principal Investigator

AbbVie

Eligibility Criteria

This trial is for adults with a primary diagnosis of panic disorder, having had at least 8 panic attacks in the past month and no week without panic attacks. They must have a certain body weight and BMI, and not be undergoing any new psychotherapy or have significant psychiatric comorbidities or serious health issues.

Inclusion Criteria

I have been diagnosed with panic disorder.

Minimum of 8 panic attacks in the month prior to Screening Visit, with no week free of panic attacks. At least 4 panic attacks in the 2 weeks prior to Baseline Visit, with no week free of panic attacks

PDSS total score ≥12 at Screening and Baseline Visits

Exclusion Criteria

I do not have any major heart, lung, stomach, kidney, liver, blood, immune system, or brain diseases.

Current significant psychiatric comorbidity

I have recently started a recognized therapy like CBT.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Titration

Participants receive darigabat or placebo, up to a maximum dose of 12.5 mg, orally, BID for two weeks

2 weeks

Maintenance Treatment

Participants receive darigabat 25 mg or placebo, orally, BID for 12 weeks

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• Darigabat (GABA receptor modulator)

Trial Overview The study tests the effectiveness, safety, and tolerability of darigabat (25 mg twice daily) against a placebo in individuals with panic disorder. Participants will randomly receive either darigabat or placebo to compare outcomes.

Participant Groups

Group I: Darigabat Experimental Treatment 1 Intervention

Participants will receive darigabat, up to a maximum dose of 12.5 mg, orally, BID, for two weeks in the Titration Period and thereafter, 25 mg, orally, BID for 12 weeks in the Maintenance Treatment Period.

Group II: Placebo Placebo Group 1 Intervention

Participants will receive darigabat matching placebo, orally, BID for 2 weeks during the Titration period and thereafter for 12 weeks during the Maintenance Treatment Period.

Who Is Running the Clinical Trial?

AbbVie

Lead Sponsor

Trials

1,079

Recruited

535,000+

Founded

2013

Headquarters

North Chicago, USA

Known For

Immunology treatments

Top Products

Humira (adalimumab), Skyrizi (risankizumab), Rinvoq (upadacitinib)

Dr. Roopal Thakkar

AbbVie

Chief Medical Officer since 2023

MD from Wayne State University School of Medicine

Robert A. Michael

AbbVie

Chief Executive Officer

Bachelor's degree in Finance from the University of Illinois

Cerevel Therapeutics, LLC

Lead Sponsor

Trials

37

Recruited

5,500+

Findings from Research

Quetiapine extended-release was not effective in treating treatment-resistant panic disorder compared to a placebo, indicating that it may not be a viable option for patients who do not respond to standard treatments.

Switching from cognitive behavioral therapy (CBT) to medications like paroxetine or citalopram has shown better outcomes for patients who did not respond to CBT, suggesting that a change in treatment strategy can be beneficial.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Management of Treatment-Resistant Panic Disorder. Perna, G., Caldirola, D.[2022]

Despite SSRIs and CBT being effective first-line treatments for panic disorder, treatment resistance is common due to factors like inadequate trial duration and poor tolerability.

For patients who do not respond to SSRIs, alternative strategies include combining treatments with benzodiazepines or TCAs, using newer antidepressants like venlafaxine XR, or exploring CBT, which shows preliminary efficacy in medication-resistant cases.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Management of treatment-refractory panic disorder. Mathew, SJ., Coplan, JD., Gorman, JM.[2022]

In a study of 135 patients with panic disorder, moclobemide (450 mg/day) was found to be as effective as clomipramine (150 mg/day) after 8 weeks, with similar rates of treatment response (49% for moclobemide vs. 53% for clomipramine).

Moclobemide had a better safety profile, with fewer adverse effects compared to clomipramine, which had higher rates of anticholinergic side effects; common side effects for moclobemide included headache and dizziness, but were generally infrequent.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Krüger, MB., Dahl, AA.[2022]

Panic disorder is characterized by recurrent, unexpected panic attacks and can lead to significant behavioral changes and anticipatory anxiety, making early diagnosis crucial for effective treatment.

Both pharmacologic and non-pharmacologic cognitive-behavioral therapies have been shown to be safe and effective in treating panic disorder, helping patients regain confidence and improve their daily functioning.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Panic disorder: effective treatment options. Saeed, SA., Bruce, TJ.[2007]

In an 8-week trial involving 10 patients with refractory panic disorder, olanzapine significantly reduced the average number of panic attacks from 6.1 per week to 1.1, with 50% of participants becoming panic-free by the end of treatment.

The study found that olanzapine was generally safe, with no significant changes in vital signs or major side effects, although 60% of participants experienced weight gain, indicating the need for further research to confirm its efficacy and safety in larger populations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Potential effectiveness and safety of olanzapine in refractory panic disorder. Hollifield, M., Thompson, PM., Ruiz, JE., et al.[2022]

References

1. Switzerland pubmed.ncbi.nlm.nih.gov

Management of Treatment-Resistant Panic Disorder. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

Panic disorder: efficacy of current treatments. [2009]

3. United States pubmed.ncbi.nlm.nih.gov

The place of selective serotonin reuptake inhibitors in the treatment of panic disorder. [2022]

4. United States pubmed.ncbi.nlm.nih.gov

Management of treatment-refractory panic disorder. [2022]

5. Germany pubmed.ncbi.nlm.nih.gov

Effects of the GABA-reuptake inhibitor tiagabine on panic and anxiety in patients with panic disorder. [2018]

6. Germany pubmed.ncbi.nlm.nih.gov

The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. [2022]

7. United States pubmed.ncbi.nlm.nih.gov

Panic disorder: effective treatment options. [2007]

8. United States pubmed.ncbi.nlm.nih.gov

Potential effectiveness and safety of olanzapine in refractory panic disorder. [2022]